fresh frozen plasma + methylprednisolone + rituximab

This is a combination therapy consisting of three distinct components: 1. **Fresh Frozen Plasma (FFP)**: The liquid portion of human blood that has been centrifuged, separated, and frozen solid at -18°C or colder within six hours of collection. FFP contains clotting factors and other blood proteins used to treat bleeding disorders or coagulation factor deficiencies. 2. **Methylprednisolone**: A synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. It works by decreasing inflammation and modifying the body's immune response. 3. **Rituximab**: A chimeric monoclonal antibody that targets CD20, a surface antigen present on B lymphocytes. It depletes normal and pathogenic B cells while sparing plasma cells and hematopoietic stem cells. This combination is likely used in the treatment of certain autoimmune disorders, particularly those involving blood components or requiring immunosuppression and B-cell depletion.

Other names

FFP + HDMP + RituximabFresh frozen plasma + high dose methylprednisolone + rituximab